HUAREN MEDICAL TECHNOLOGY
NEWS
03
2024-01
On 28 December 2023, Guangxi Standardization Association announced the list of the seventh batch of standardisation expert database of Guangxi Standardization Association, and Wei Zhumei, head of animal centre of Guangxi Huaren Medical Science and Technology Group and deputy general manager of Guangxi Huaren Jiying Biotechnology Co Ltd, was selected as an expert in non-human primate experimental animal research.
View More21
2023-11
Monsoon Chairman and his team were invited to participate in the 3rd Zhou Shang Conference 2023
From 15th November to 16th November 2023, the 3rd Zhou Shang Conference was held in Zhoukou City, Henan Province. Ji Feng, Chairman of Guangxi Huaren Medical Science and Technology Group, Yang Dengfeng, Technical Director, Xiao Kai and He Wengtan, Deputy General Managers of subsidiaries, attended the meeting.
View More19
2023-09
On September 14, Professor Wan Qi, Director of Neural Regeneration and Rehabilitation Research Institute of Qingdao University, visited Huaren Medical Science and Technology Group, accompanied by Chairman of Huaren Medical Science and Technology Group, Mr. Ji Feng, President Zeng Yong, and Director of Animal Centre, Mr. Wei Zhumei, and had a discussion on in-depth cooperation between industry, academia and research. Zhang Pengfei, project supervisor of the Group's Animal Experiment Department, Huang Xiaojiao, technical supervisor, and Pan Mengxian, topic leader, attended the discussion.
View More11
2023-09
Cell culture is the most basic operation for cell experiments. Through cell culture, we can obtain a large number of cells, which can be used for further research on cell function and signalling pathways, so the quality of cell culture will directly affect the subsequent cell experiments and the accuracy of the results.
View More11
2023-09
An active targeting approach for the treatment of osteosarcoma with nanodelivery systems
Osteosarcoma is the most common in situ tumour of bone, accounting for approximately 35% of bone malignancies. The main symptoms of patients with osteosarcoma include restricted mobility, swelling, severe pain, and pathological fracture, and approximately 10-20% of patients have metastases at the time of their initial consultation. Conventional treatment includes early surgical resection and adjuvant chemotherapy, but a larger proportion of patients still respond poorly to treatment. The current first-line chemotherapeutic agents include adriamycin, cisplatin and methotrexate, which synergistically exert anti-tumour effects through different mechanisms of action, but due to the lack of selectivity of these agents and more pronounced systemic toxicity when applied in high doses, new therapeutic approaches need to be explored.
View More04
2023-09
On August 31st, Zeng Yong, President of Guangxi Huaren Medical Technology Group, warmly received more than 50 trainees of "Guangxi University College of Continuing Education 2023 Yufeng District Committee Management Cadres Learning and Implementing the Party's Twentieth Thematic Training Class (Accelerating the Promotion of Industrial Revitalisation)" who came to visit and study in the Joint Experimental Centre.
View MoreSUBSCRIPTION INFORMATION
We will send you real-time information regularly!
Guangxi Huaren Medical Technology Group Co., Ltd.
Tel: 400-138-8669/ 0771-611-0603
Address: 15th Floor, Building A, Biyuan Center, Wuxiang New District, Nanning City, China (Guangxi) Pilot Free Trade Zone
Huaren Medical Technology
Huaren Medical Research
Hua Ren Cell said